News | February 02, 2022
Windlas Biotech concludes SAHPRA audit with an all-clear sign
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
The transaction is expected to close in the first quarter of 2022
He has over 22 years of experience in pharmaceutical sales & business development
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Subscribe To Our Newsletter & Stay Updated
